Previous pharmacovigilance analysis of psychiatric AEs linked to PCSK9 inhibitors (alirocumab and evolocumab), using FAERS data from the third quarter (Q3) 2015 to Q1 2023 and applying both MHRA and IC methods, identified memory loss as a highly significant signal [ 24 ].
← all excerpts
Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence.
1
—
—